BOSTON , Jan. 13, 2025 /PRNewswire/ — The Centering Healthcare Institute (CHI) is thrilled to announce the launch of its Strategic Plan, a comprehensive approach to improving maternal and infant health outcomes across the United States. With a strong focus on equity and collaboration, this plan lays the groundwork for CHI to drive meaningful, measurable change… Continue reading Centering Healthcare Institute Introduces Strategic Plan to Transform Maternal Healthcare Nationwide
Tag: Morgan
NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare
SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) — J.P. Morgan Healthcare Conference — NVIDIA today announced new partnerships to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI. The convergence of AI, accelerated computing and biological data is turning healthcare… Continue reading NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare
Trillium Flow Technologies rondt herfinanciering succesvol af
STAMFORD, Conn., 13 januari 2025 /PRNewswire/ — Trillium Flow Technologies (“Trillium”), een portfoliobedrijf van First Reserve en een wereldwijde ontwerper, fabrikant en leverancier van aftermarket-diensten voor hoogtechnologische kleppen en pompen voor gebruik in kritieke infrastructuursectoren zoals kernenergie, water, afvalwater en industriële verwerking, kondigt verheugd aan dat het haar herfinanciering succesvol heeft afgerond in december 2024.… Continue reading Trillium Flow Technologies rondt herfinanciering succesvol af
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDETM (molecular degraders of extracellular proteins) platform and the next generation TRAPTM (targeted removal of aberrant protein) degraders, including: IgA Nephropathy (IgAN) program: First-in-human dosing with BHV-1400, a next generation TRAP degrader, achieved… Continue reading Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
Akebia Therapeutics Announces Multiple Positive Business Updates
New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business… Continue reading Akebia Therapeutics Announces Multiple Positive Business Updates
Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED at the 43rd Annual… Continue reading Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash… Continue reading Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study —… Continue reading Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study —… Continue reading Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates. 43rd Annual J.P. Morgan Healthcare ConferenceMonday, January 13th,… Continue reading IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance